Centrus (LEU) Defends $185.51 as the Only U.S. Enricher Trades at 77x Earnings for 2029 Capacity

Centrus Energy finished Friday at $194.78 after ranging $185.51 to $196.88, an 11-point band on a single session. That is a 6.1% high-to-low move in a company that generated $176.1 million of revenue last quarter and holds a $4.5 billion backlog. Volatility is the defining feature of this stock, and it has been all year.

The recent path shows how violent it has been. LEU sank 6% to $172.68 on August 20 during a broad nuclear selloff, bounced 2% to $181.44 on August 25 as the group staged an oversold reversal, and closed the month near $195. Earlier in August it traded around $187.63 and around $188. In May it closed at $179.36. The stock has covered a $22 range in three weeks without a single company-specific development to justify either end.

The year-to-date number is the one holders feel. LEU is down roughly 31% in 2026 and down 17.9% over the trailing twelve months. Against the 52-week high of $464.25, Friday's close sits 58% lower.

That drawdown is worth putting alongside the five-year record. Centrus has returned approximately 6.7 times for shareholders over five years. A 58% retracement from a peak reached after a 570% run is a normal correction inside a violent uptrend, not a broken thesis — but it sets a very high bar for what comes next.

The sector context is unforgiving. On August 27, Oklo fell 4.96% to $40.42, NuScale 4.93% to $9.26, Uranium Energy 8.41% to $12.47 and the Global X Uranium ETF 5.46% to $45.73, against an S&P 500 that closed flat. Nuclear equity is being repriced on the discount rate, and Centrus trades with the theme regardless of its own numbers.

The thesis for this forecast: Centrus is the only U.S. company with an operating domestic uranium enrichment plant, it just converted a government demonstration contract into a $1.07 billion commercial award, and it holds a $4.5 billion backlog running to 2040. It also earns most of that backlog after 2029, trades at 77 times earnings, and still depends on a Russian state entity for its largest source of supply.

The Chart: $142.13 Floor, $464.25 Ceiling, and a 58% Drawdown

The technical structure is a corrective phase inside a multi-year uptrend, and the levels are far apart.

The 52-week range runs $142.13 to $464.25. Friday's $194.78 sits 37% above the low and 58% below the high. That is not a range in any tradeable sense — it is a distribution of outcomes.

The 2025 peak near $460 completed what several chart readers describe as a five-wave impulse from the 2024 base, with everything since developing as a corrective ABC structure. The pullback took price from roughly $440 to $260 in the first leg, then extended toward the current levels.

Immediate support is $185.51, Friday's session low. Below it, $181.44 marks the August 25 bounce level and $172.68 the August 20 low. A close under $172.68 puts $142.13 back in play as the structural floor — a further 27% decline from current levels.

Immediate resistance is $196.88, Friday's high, followed by the round $200 handle. Above that, $216 corresponds to Stifel's revised target and $253.25 to the consensus twelve-month price target. Reclaiming $260 would confirm the corrective phase has ended, and the $300 level marks Northland's unchanged Buy target.

The intraday picture is more constructive than the daily. Technical screens across shorter timeframes have consistently registered strong buy signals from the hourly through the weekly, with monthly turning neutral — a configuration that describes a stock bouncing hard off oversold conditions inside a longer downtrend.

Volume and volatility both argue for wide stops. A stock that routinely moves 6% intraday on sector flow rather than company news cannot be managed with tight risk parameters.

The key observation for anyone trading this: Centrus is currently a beta expression of the nuclear fuel theme rather than an idiosyncratic story. It fell 6% on a day NuScale reported $75,000 of revenue, despite Centrus reporting $176.1 million. That correlation breaks when a contract lands or a guidance revision hits, and not before.

Q2 Revenue of $176.1 Million Beat Consensus by 18%

The second quarter, reported August 6, was a genuine beat on every top-line measure.

Revenue came in at $176.1 million, up 14% year over year, against a consensus that sat between $148.76 million and $149.85 million. That is an 18% to 20% beat. Adjusted earnings per share of $1.77 exceeded estimates by 82.5%.

Management reaffirmed full-year 2026 consolidated revenue guidance of $450 million to $500 million and maintained capital expenditure guidance at $350 million to $500 million. Full-year 2025 revenue was $448.70 million, up 1.52% from $442.00 million, with earnings of $77.80 million, up 6.28%.

The revenue trajectory embedded in that guidance is the part most coverage skipped. With $176.1 million booked in the second quarter and the full year guided to $450 million to $500 million, the back half implies a sharp deceleration. Consensus for the third quarter sits near $66.39 million — a 62% sequential decline.

That lumpiness is structural rather than a warning. Centrus recognises revenue on separative work unit deliveries under long-term utility contracts, and delivery schedules cluster. Quarter-to-quarter comparisons in this business are close to meaningless; the annual figure and the backlog are what matter.

Operationally the quarter delivered. Management raised the Piketon hiring target to more than 175 employees from more than 100. The first Oak Ridge centrifuge remains due in 2026. Contracts with all partners identified as critical to the industrial expansion are on track to be finalised during the year.

CEO Amir Vexler framed it as another strong quarter of financial and operational progress including a number of commercial wins for the future enrichment business.

The company operates two segments. Low-Enriched Uranium sells SWU components, natural uranium hexafluoride, uranium concentrates, conversion services and enriched uranium products to utilities operating nuclear plants across the United States, Japan, the Netherlands and internationally. Technical Solutions provides advanced engineering, design and manufacturing services to government and private-sector customers and is deploying the advanced fuel production capability.

Centrus was formerly USEC Inc. and adopted the current name in September 2014.

Net Income Fell 42% While Revenue Rose 14%

The margin story is where the quarter gets uncomfortable, and it is the number the market punished.

Net income came in at $16.8 million, down 42% from the second quarter of 2025. GAAP earnings per share were $0.84 against $1.63 a year earlier. Profit margin compressed to 9.5% from 19%. Trailing twelve-month figures show revenue of $473.9 million and net income of $48.5 million, with margins at 10.2% against 24% a year earlier.

Revenue up 14%. Net income down 42%. Margin cut roughly in half.

The stated cause is higher expenses, and the composition matters. Centrus is spending ahead of a commercial build-out that does not generate revenue until 2029: workforce expansion at Piketon toward 175-plus employees, centrifuge manufacturing at Oak Ridge, engineering for the commercial-scale HALEU cascade, and the fixed costs of operating the existing demonstration cascade on a commercial basis.

That is investment, not deterioration. It is also a multi-year margin drag that the market is only beginning to model.

Capital expenditure guidance of $350 million to $500 million for 2026 against revenue guidance of $450 million to $500 million puts the point sharply. Centrus plans to spend nearly its entire annual revenue on capacity this year. Consensus forecasts earnings growing 6.02% per year and revenue 4.1% per year over the next three years — slower than the broader U.S. market's 12.9% revenue comparison and barely ahead of the oil and gas industry's 1.4%.

Over the last three years earnings per share has increased by roughly 3% annually while the share price has increased 65% per year. That gap is the entire valuation problem in one sentence: the equity has been repriced on the story, not the earnings.

The offset is contract structure. Centrus removed financial contingencies from over $3 billion in customer contracts during the quarter, converting conditional commitments into firm obligations. That is a real de-risking of the backlog and it happened in the same quarter margins halved.

The $4.5 Billion Backlog Through 2040 Is the Real Asset

Order book is the single most defensible number Centrus reports, and it went up materially.

The company raised its backlog to $4.5 billion extending through 2040. Against 2026 revenue guidance of $450 million to $500 million, that is roughly nine to ten years of current-run-rate revenue already contracted.

More important than the headline figure was the contractual quality upgrade. Centrus removed financial contingencies from more than $3 billion of customer contracts, converting them from conditional to firm. Backlog with contingencies attached is a pipeline; backlog without them is revenue with a delivery date.

The additions came from the advanced reactor complex. On August 6, Centrus signed a definitive agreement with X-energy to provide enrichment services for both low-enriched uranium and high-assay low-enriched uranium, supporting the Xe-100 small modular reactor pipeline and TRISO fuel fabrication. The contract includes X-energy prepayments to Centrus, which is the critical detail: the customer is helping fund the capacity build-out. The planned project brings investment and jobs to Eastern Tennessee.

X-energy is not a speculative counterparty. It reported second-quarter revenue of $54.6 million, up 154% year over year from $21.5 million.

Separately, Centrus has committed HALEU deliveries from the American Centrifuge Plant to Oklo for Aurora powerhouses in Ohio, with deliveries beginning in 2029.

Tight supply and robust demand continue to drive favourable pricing and order momentum, which is the pricing environment a contracted book gets marked into.

The bear counterpoint is concentration. Despite the backlog, Centrus remains highly dependent on a handful of long-term government and utility customers. Any loss, renegotiation or deferral as global nuclear policy evolves could produce sharp revenue volatility and reduce earnings predictability across the coming decade.

A $4.5 billion book resting on a small number of counterparties is a different asset than a $4.5 billion book spread across fifty utilities. Both are real. Only one is diversified.

The $1.07 Billion DOE Award Turned a Demo Into a Factory

The transition from government demonstration to commercial production is the most important thing that happened to this company in 2026.

On January 5, 2026, the Department of Energy announced that Centrus subsidiary American Centrifuge Operating LLC was awarded a $900.0 million task order to expand the Piketon, Ohio enrichment facility to include commercial-scale HALEU production. The award includes options, at DOE's discretion, for up to an additional $170.0 million to produce and deliver HALEU to the Department. Total contract value with all options is $1.07 billion.

Centrus signed the contract finalising those terms in early July. Vexler framed it as pivoting from a technology demonstration contract to a larger contract aimed at commercial-scale production.

The demonstration history explains why DOE moved. In 2019 the Department awarded Centrus a contract to license and construct a cascade of advanced centrifuges at Piketon. A competitively awarded three-phase follow-on contract in 2022 brought the cascade into production. Phase I completed in late 2023 with the delivery of the first 20 kilograms of HALEU — making Piketon the first U.S.-owned, U.S.-technology uranium enrichment plant to begin production in 70 years. Phase II delivered 900 kilograms. DOE exercised Option 1a of Phase 3 on June 17, 2025 at a contract value of $108.2 million running through June 30, 2026, and Centrus completed the final 900 kilograms in mid-June, two weeks ahead of schedule, taking cumulative production above 1,900 kilograms.

DOE retains the ability to exercise three optional periods for up to nine additional years of production beyond the base contract — at its sole discretion and subject to Congressional appropriations.

That last clause is the risk. Centrus states plainly in its filings that if federal funding is delayed, reduced or terminated as a result of changes in policy or budgetary priorities, it could have a material adverse impact on operations and on the ability to deploy American Centrifuge technology.

The company's revenue base is a government relationship. Government relationships are subject to appropriations.

Piketon Does Not Produce Commercially Until 2029

The timeline is the single most underweighted fact in the bull case.

Commercial production at Piketon remains targeted for 2029. The first new capacity from the DOE-funded expansion is expected online that year. The Oklo HALEU deliveries begin in 2029. The X-energy volumes support reactors that have not been built.

That is three years of capital spending, hiring and engineering before the first commercial molecule of expanded capacity ships.

The interim plan is to operate the existing HALEU cascade privately on a commercial basis to supply near-term customer needs. That cascade is 16 AC100M gas centrifuge machines. A full-scale HALEU cascade requires 120 individual machines. Centrus is running roughly 13% of a single full cascade while the market values it as an enrichment platform.

The physics explains the scale problem. The AC100M feeds uranium hexafluoride heated to a gaseous state into a rotor spinning at high speed inside a steel casing, using centrifugal force to concentrate heavier U-238 at the rotor wall and lighter U-235 toward the centre, with streams cascading to successive machines. Centrus uses 4.95% LEU feed material for its planned HALEU cascade, which means roughly 85% of the separative work has already been done before the material enters the machine.

Building 120 machines is a manufacturing problem, not a research problem — the first Oak Ridge centrifuge is due this year. But manufacturing at that scale takes years and capital, which is why capex guidance runs $350 million to $500 million against $450 million to $500 million of revenue.

Centrus has been explicit that the enrichment capacity build-out will be based on customer demand and capital resources. That is a conditional commitment, not a fixed plan.

An investor buying LEU today is funding three years of construction to reach a 2029 revenue inflection, at 77 times trailing earnings. That is the trade.

X-energy and Oklo Prepaid for Fuel That Ships in 2029

The customer prepayment structure is genuinely differentiated and it deserves more credit than the market is giving it.

The X-energy definitive agreement, announced August 6, covers enrichment services for both LEU and HALEU with quantities supporting the Xe-100 reactor pipeline and TRISO fuel fabrication. Critically, the contract includes X-energy prepayments to Centrus.

Prepaid offtake solves the hardest problem in capital-intensive nuclear fuel: financing capacity before demand is provable. Rather than raising equity or debt against a 2029 revenue stream, Centrus is receiving customer cash today to build the plant that will serve those customers later. That is the same structure that let LNG developers reach final investment decision a decade ago, and it is far superior to the ATM-and-dilute model most pre-revenue nuclear names are running.

The Oklo relationship works similarly on the demand side. HALEU deliveries from the American Centrifuge Plant to Oklo for Aurora powerhouses in Ohio begin in 2029, with co-location economics reducing capital intensity for both parties.

Analysts framing the transition describe Centrus moving from a low-margin broker — buying SWU from suppliers and reselling to utilities — toward a vertically integrated, high-margin nuclear fuel producer. That shift is the entire re-rating case, and the prepayments are what make it financeable.

The risk sits on the counterparty side rather than the Centrus side. X-energy's Xe-100 has not been deployed commercially. Oklo's Aurora has not achieved criticality. Both are pre-revenue reactor developers dependent on regulatory approval and capital markets that have de-rated hard in 2026 — Oklo is down 42% year to date.

Prepayments from customers who may not exist in 2029 are prepayments with recourse questions attached. Centrus keeps the cash either way, but the volumes that justify a 120-machine cascade evaporate if the reactor buildout slips.

Execution risk on new enrichment facilities and the timing of reactor deployment are the two variables that determine whether the backlog converts.

The TENEX Problem: Russia Is Still the Largest Supplier

The most serious risk in this business is buried in the filings and almost never appears in bullish coverage.

Under a 2011 contract, TENEX Joint Stock Company — a Russian government-owned entity — serves as Centrus's largest supplier of low-enriched uranium for delivery to U.S. and international customers. Centrus states in its 10-K that it currently relies on the TENEX Supply Contract as a significant supply source to meet delivery obligations.

The legal environment around that contract is hostile from both directions. The Import Ban Act bans imports of Russian LEU into the United States, with deliveries from Russia set to end in 2028. Separately, a Russian decree prohibits LEU exports out of Russia in the absence of a specific license. On November 14, 2024, the Russian Federation rescinded TENEX's general license to export LEU to the United States, requiring TENEX to obtain a specific export license for each shipment.

Centrus's own risk language is blunt: such bans or tariffs on LEU imports or exports from Russia could have a material impact on operations and liquidity. The filings enumerate the failure modes — sanctions on TENEX or Rosatom, TENEX's inability or unwillingness to deliver or receive payments, a directive from the Russian government to limit transactions, and disputes with third-party counterparties if Centrus cannot receive timely deliveries.

The company also flags a potential inability to secure additional waivers or exceptions from the ban in a timely manner or at all.

This is the structural irony of the investment case. The company positioned as America's answer to Russian enrichment dominance currently depends on Russian enrichment to service its book. The 2028 deadline is what converts that dependency from a risk into a forcing function — and it is the same year the Piketon expansion is meant to be ramping.

Short-term risks flagged by analysts include USTR maritime tariffs, Russian export license delays, and DOE funding gaps, with the potential to create a temporary liquidity crunch before 2029.

That is the gap between the demonstration cascade and the commercial plant, and it is three years wide.

Valuation: 77 Times Earnings Against a 13 Times Industry Average

There is no version of the valuation math that makes this stock cheap on current earnings.

Centrus carries a price-to-earnings ratio of 77.2 times against an estimated fair P/E of 12.1 times and an industry average of 13 times. An earlier reading put the multiple at 58.2 times against a US oil and gas industry at 14.6 times, a peer average at 11.2 times and a fair ratio of 10.9 times. The stock passes 0 of 6 standard valuation checks.

Market capitalisation sits around $3.5 billion against trailing revenue of $473.9 million and net income of $48.5 million.

The bull rebuttal is that trailing earnings are the wrong denominator for a company whose contracted revenue extends to 2040 and whose commercial capacity comes online in 2029. Discounted cash flow narratives put fair value as high as $609.90, with the most-followed narrative more recently marking it near $190 — almost exactly in line with the current price.

That collapse in narrative fair value from $609.90 toward $190 is the single most honest datapoint in the coverage. The model did not change; the assumptions did.

The analyst target framework tells the same story. Consensus fair value moved to $257.47 from $269.38 as analysts factored in higher perceived risk, shifting revenue and margin assumptions, and a materially higher future P/E multiple. Individual targets range from $170 to $337 — a spread of 96% between the low and the high on identical public information.

Eighteen analysts carry an average rating of Buy with a twelve-month target of $253.25, implying roughly 30% upside from Friday's close.

The honest framing: LEU is not a value stock and does not pretend to be. It is a strategic asset with a government contract, a contracted book, and a 2029 inflection. Whether 77 times trailing earnings is the right price for that depends entirely on the discount rate applied to 2029 cash flows — and with the thirty-year Treasury at 5.21% and September Fed hike odds at 58%, that discount rate has been rising all month.

Short Interest at 27.5% of Float Is the Squeeze Setup

The positioning data is the most asymmetric element of this stock right now.

Short interest stands at 5.0 million shares, up 14.1% from the previous reporting period and representing 27.5% of the float. Since August 2025, short interest has increased 40.7%.

More than a quarter of the tradeable float is sold short in a stock that moves 6% intraday on sector flow. That combination produces the price behaviour observed all month: violent 5% to 6% down days followed by equally violent bounces, with neither direction sustaining.

The bear thesis behind that positioning is coherent. Seventy-seven times earnings, margins halving from 24% to 10.2%, capex consuming nearly all revenue, a 2029 commercial start, dependence on Congressional appropriations, and a Russian state supplier under a ban. Those are real objections.

But 27.5% of float is a crowded expression of them. Any of three catalysts forces covering: a DOE option exercise for additional production years, a new prepaid offtake agreement of the X-energy type, or a Federal Reserve hold in September that lifts the whole long-duration complex.

Insider activity has been mixed. Form 4 filings over the past 90 days show selling, though the pattern is consistent with routine portfolio management, Rule 10b5-1 plans, tax planning and compensation-related dispositions rather than a directional view.

The rights plan is a separate structural detail worth noting. Shareholders approved an extension on June 18, 2026, preserving the company's net operating loss carryforwards. It remains in effect through June 30, 2029 — coincidentally the year commercial production begins. Those NOLs shield future taxable income, which is a real and under-modelled asset once Piketon scales.

Next earnings land November 11, 2026. That is the next scheduled event capable of resolving the positioning standoff.

The Sector: Uranium Down, Rates Up, and LEU Trades With Both

Centrus does not trade on its own fundamentals right now, and the evidence is unambiguous.

On August 20, LEU fell 6% to $172.68 on the same session NuScale fell 5% and Oklo fell 5%, with the Global X Uranium ETF down 3% to $43.62. The proximate trigger was NuScale reporting $75,000 of quarterly revenue — a company with no operational relationship to Centrus, which had reported $176.1 million two weeks earlier.

On August 27 the pattern repeated: Oklo down 4.96% to $40.42, NuScale down 4.93% to $9.26, Uranium Energy down 8.41% to $12.47, URA down 5.46% to $45.73, against a flat S&P 500. On August 25 the whole group bounced together, with LEU up 2% to $181.44, Uranium Energy up 6% and Oklo up 5%.

The mechanism is the discount rate. Nuclear equities are especially sensitive to interest-rate anxiety because most advanced reactor projects require substantial capital long before generating commercial revenue. With the two-year Treasury at 4.36%, the thirty-year at 5.21%, and September Fed hike odds at 58% after Warsh's Jackson Hole remarks, every long-duration cash flow in the market is being marked down.

The differentiation argument is that Centrus already generates revenue from nuclear fuel and enrichment services, which sets it apart from pre-revenue developers. That distinction is real and it has not protected the stock.

Where the sector bifurcates properly is against the utilities. Constellation Energy trades at a trailing P/E near 22 with EPS of $11.51 and reaffirmed 2026 guidance of $11 to $12. Vistra reaffirmed 2026 adjusted EBITDA guidance of $6.8 billion to $7.6 billion. Both trade on earnings and long-dated hyperscaler power purchase agreements, and both have held up while the fuel and developer complex de-rated.

Centrus sits between them: real revenue, real contracts, real government backing, and a valuation multiple that belongs to the developer cohort. That is why it falls with the developers and does not rally with the utilities.

Analysts Cut Targets to a $253 Mean While Keeping Buy Ratings

The sell-side revision cycle through August was uniformly downward on price and unchanged on conviction.

Stifel cut its target to $216 from $246 on August 25. JPMorgan lowered to $178 from $236 while keeping a Neutral rating. Morgan Stanley initiated or maintained an Equalweight rating with a target attached. Roth Capital moved the other direction, raising to $188 from $171 on August 6 following the earnings beat. Another firm raised to $185 on a stronger outlook while keeping its rating unchanged on long-term nuclear cycle grounds. Northland Securities held a Buy with an unchanged $300 target, citing the growing backlog and HALEU leadership.

Across 18 analysts the average rating is Buy with a twelve-month target of $253.25, roughly 30% above Friday's close. The full target range spans $170 to $337.

That configuration — targets falling, ratings holding — mirrors what happened across the entire nuclear complex in August. Analysts are not abandoning the thesis. They are extending the timeline and raising the discount rate.

Coverage framing captures the split. One note described Centrus's growing backlog and HALEU leadership as supporting a Buy rating with an unchanged $300 target. Another described the company as transitioning from a low-margin broker to a vertically integrated, high-margin nuclear fuel leader, leveraging co-location with Oklo and Palantir's AIP for capital efficiency, while flagging USTR maritime tariffs, Russian export license delays and DOE funding gaps as short-term risks that could create a temporary liquidity crunch before 2029.

The bear case as articulated by the same sources: heavy dependence on a handful of long-term government and utility customers, with any loss, renegotiation or deferral capable of producing sharp revenue volatility over the coming decade.

At $194.78, Centrus trades about 23% below the consensus target and roughly 42% below the top of the analyst range. Whether that discount is a bargain or a warning is exactly the question the market has been unable to resolve for three months.

Centrus Energy Stock Forecast: $172 Downside, $253 Upside, Hold Below $200

Centrus at $194.78 is the only American company operating a domestic uranium enrichment plant, holding a $4.5 billion backlog and a $1.07 billion government award, priced at 77 times trailing earnings for capacity that starts producing commercially in 2029.

The bull case has five legs. Second-quarter revenue of $176.1 million beat consensus by 18% and rose 14% year over year, with 2026 guidance reaffirmed at $450 million to $500 million. Backlog was raised to $4.5 billion through 2040 and financial contingencies were removed from more than $3 billion of customer contracts, converting pipeline into firm obligation. The $900 million DOE task order — $1.07 billion with options — moved Piketon from technology demonstration to commercial-scale construction. The X-energy definitive agreement includes customer prepayments that fund capacity without dilution, and Oklo deliveries begin in 2029. And short interest at 27.5% of float against a stock that already fell 58% from its high is a squeeze setup waiting for one catalyst.

The bear case has five. Net income fell 42% to $16.8 million while margins halved from 19% to 9.5%, and trailing margins are 10.2% against 24% a year earlier. Capex guidance of $350 million to $500 million consumes nearly all of guided revenue. A 77.2 times P/E sits against a 13 times industry average and 0 of 6 valuation checks passed. Commercial production does not begin until 2029, and DOE options are at the Department's sole discretion subject to Congressional appropriations. And TENEX, a Russian state entity operating under an import ban and an export decree, remains the largest supplier.

The verdict is Hold, with a trading bias to accumulate below $180 and trim into $250. Base case through the November 11 earnings report: $172 to $253, midpoint near $210. Upside target on a daily close above $200 is $216, then the $253.25 consensus; a new prepaid offtake agreement or a DOE option exercise takes it toward $300. Downside target on a close below $185.51 is $172.68, then $142.13 at the 52-week low.

This is a strategic asset priced as a growth stock. The backlog is real. The 2029 date is also real.

That's TradingNEWS